<VariationArchive VariationID="16423" VariationName="NM_000138.5(FBN1):c.7455_7821del" VariationType="Deletion" Accession="VCV000016423" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2013-04-04" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="31462" VariationID="16423">
      <GeneList>
        <Gene Symbol="FBN1" FullName="fibrillin 1" GeneID="2200" HGNC_ID="HGNC:3603" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>15q21.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="48408313" stop="48645709" display_start="48408313" display_stop="48645709" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="48700502" stop="48937984" display_start="48700502" display_stop="48937984" Strand="-" />
          </Location>
          <OMIM>134797</OMIM>
          <Haploinsufficiency last_evaluated="2019-12-04" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FBN1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2019-12-04" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FBN1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000138.5(FBN1):c.7455_7821del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>15q21.1</CytogeneticLocation>
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_778t1" sequenceAccession="LRG_778t1" change="c.7455_7821del">
            <Expression>LRG_778t1:c.7455_7821del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000138.5" sequenceAccession="NM_000138" sequenceVersion="5" change="c.7455_7821del" MANESelect="true">
            <Expression>NM_000138.5:c.7455_7821del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA645373004" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="134797.0003" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="GenomicLocationNotEstablished">The length of the genomic deletion was defined as &gt; 1kb, but the breakpoints were not reported in the paper by  Kainulainen et al., 1992, (PubMed 1631074).</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000138.5(FBN1):c.7455_7821del AND Marfan syndrome" Accession="RCV000017885" Version="24">
        <ClassifiedConditionList TraitSetID="5402">
          <ClassifiedCondition DB="MedGen" ID="C0024796">Marfan syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1992-07-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1992-07-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2013-04-04" MostRecentSubmission="2024-06-09">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">1631074</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="5402" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2645" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Marfan syndrome type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Marfan's syndrome</ElementValue>
                <XRef ID="Marfan+syndrome/4466" DB="Genetic Alliance" />
                <XRef ID="19346006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Marfan syndrome</ElementValue>
                <XRef ID="MONDO:0007947" DB="MONDO" />
                <XRef ID="19346006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Marfan syndrome, classic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MARFAN SYNDROME, TYPE I</ElementValue>
                <XRef Type="MIM" ID="154700" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MFS1</ElementValue>
                <XRef Type="MIM" ID="154700" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">MFS</ElementValue>
                <XRef Type="MIM" ID="154700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">FBN1-related Marfan syndrome (Marfan syndrome), a systemic disorder of connective tissue with a high degree of clinical variability, comprises a broad phenotypic continuum ranging from mild (features of Marfan syndrome in one or a few systems) to severe and rapidly progressive neonatal multiorgan disease. Cardinal manifestations involve the ocular, skeletal, and cardiovascular systems. Ocular findings include myopia (&gt;50% of affected individuals); ectopia lentis (seen in approximately 60% of affected individuals); and an increased risk for retinal detachment, glaucoma, and early cataracts. Skeletal system manifestations include bone overgrowth and joint laxity; disproportionately long extremities for the size of the trunk (dolichostenomelia); overgrowth of the ribs that can push the sternum in (pectus excavatum) or out (pectus carinatum); and scoliosis that ranges from mild to severe and progressive. The major morbidity and early mortality in Marfan syndrome relate to the cardiovascular system and include dilatation of the aorta at the level of the sinuses of Valsalva (predisposing to aortic tear and rupture), mitral valve prolapse with or without regurgitation, tricuspid valve prolapse, and enlargement of the proximal pulmonary artery. Severe and prolonged regurgitation of the mitral and/or aortic valve can predispose to left ventricular dysfunction and occasionally heart failure. With proper management, the life expectancy of someone with Marfan syndrome approximates that of the general population.</Attribute>
                <XRef ID="NBK1335" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6975" />
                <XRef ID="6975" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">FBN1-Related Marfan Syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301510</ID>
                <ID Source="BookShelf">NBK1335</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2010">
                <ID Source="pmc">2987429</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2012">
                <ID Source="PubMed">22237449</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2007">
                <ID Source="PubMed">17188935</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA, 2004">
                <ID Source="PubMed">15184297</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2007">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_Marfan.pdf</URL>
                <CitationText>Orphanet, Marfan Syndrome, 2007</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Loeys et al., 2010">
                <ID Source="PubMed">20591885</ID>
              </Citation>
              <Citation Type="general" Abbrev="CCS, 2014">
                <ID Source="PubMed">24882528</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173340</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="AAP, 2013">
                <ID Source="PubMed">24081994</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2017">
                <ID Source="PubMed">28161018</ID>
              </Citation>
              <XRef ID="284963" DB="Orphanet" />
              <XRef ID="558" DB="Orphanet" />
              <XRef ID="C0024796" DB="MedGen" />
              <XRef ID="MONDO:0007947" DB="MONDO" />
              <XRef Type="MIM" ID="154700" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="38164" SubmissionDate="2013-04-11" DateLastUpdated="2024-06-09" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="134797.0003_MARFAN SYNDROME" title="FBN1, 366-BP DEL_MARFAN SYNDROME" />
        <ClinVarAccession Accession="SCV000038164" DateUpdated="2024-06-09" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1992-07-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Screening 20 unrelated patients with Marfan syndrome (MFS; 154700) for mutations in fibrillin cDNA by single-strand conformation polymorphism analysis, Kainulainen et al. (1992) found 2 with mutations in heterozygous form that resulted in a shortened fibrillin polypeptide. The first mutation was a large in-frame deletion of 366 bases of the fibrillin mRNA, now known to encode exons 60-62, that resulted in a truncated but secreted polypeptide found in the fibroblast culture of the patient. The patient was a 48-year-old man with cardiovascular, eye, and skeletal features of the Marfan syndrome. He was a member of a 3-generation English pedigree, none of whom had ectopia lentis. A brother had had mitral valve replacement at 39 years of age and died suddenly at age 44. A sister also had severe mitral valve prolapse and moderate aortic root dilatation.</Attribute>
              <Citation>
                <ID Source="PubMed">1631074</ID>
              </Citation>
              <XRef DB="OMIM" ID="154700" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FBN1" />
          </GeneList>
          <Name>FBN1, 366-BP DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">366-BP DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="134797.0003" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">MARFAN SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="38164" TraitType="Disease" MappingType="Name" MappingValue="MARFAN SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C0024796" Name="Marfan syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

